Dr. McClure has over 20 years of knowledge and hands-on experience in all phases of clinical development and global operations across a broad range of therapeutic areas spanning from orphan diseases to highly prevalent diseases.

Following his medical training at Duke University, he worked at biotechnology companies in roles of increasing responsibility, including as Chief Medical Officer at several companies. Prior to joining Lifordi, Dr. McClure was CMO of Aligos Therapeutics where he was responsible for development team functions including Clinical and Clinical Operations and he designed and oversaw six first-in-human clinical trials as well as Phase 2 studies. Before Aligos, Dr. McClure was CMO of Second Genome where he directed Clinical, Operations, Regulatory, as well as Toxicology and Chemistry, Manufacturing, and Controls (CMC) functions. Earlier in his career, he was responsible for the design, execution, and interpretation of numerous clinical studies at Alios BioPharma (acquired by Johnson & Johnson), Portola Pharmaceuticals, Inc. and InterMune, Inc. (acquired by Roche).  

Dr. McClure received his medical degree from Duke University and is an alumnus of the University of California, San Diego, where he graduated summa cum laude with a B.S. in biochemistry and cell biology.